Advertisement

Perfluorocarbon Emulsions: One Approach to Intravenous Artificial Respiratory Gas Transport

  • Bruce D. Spiess
Part of the Developments in Critical Care Medicine and Anesthesiology book series (DCCA, volume 31)

Abstract

The viral infectious risks of allogeneic transfusion have recently been reduced (1). This is due to changes in viral marker testing along with surrogate risk testing using a number of biochemical tests. These data have been widely heralded with comments that the blood supply is now the safest it has ever been. This may be true; however, these data are reported from one study only and a wide range of risks associated with blood transfusion exist that will not be changed by reducing viral transmission. These risks include ABO and Rh incompatibility, graft versus host disease, volume overload, and immunosuppression leading to increased secondary infection or solid tumor recurrence. Therefore, even though viral transmission is less troublesome today than it was 5 years ago, allogeneic blood transfusion carries significant risks. For many years physicians have searched for ways to circumvent those risks. The development of safe, more efficacious, and cost effective oxygen transport medias are being investigated.

Keywords

Blood Substitute Partial Liquid Ventilation Perfluorocarbon Emulsion Sodium Chloride Potassium Oxygen Carbon Dioxide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Donahue JG, Munoz A, Ness PM, et al: The declining risk of post-transfusion hepatitis C-virus infection. N Engl J Med 327:369–373, 1992PubMedCrossRefGoogle Scholar
  2. 2.
    O’Brien RN: Diffusion coefficients of respiratory gases in a perfluorocarbon liquid. Science 217:153–155, 1982PubMedCrossRefGoogle Scholar
  3. 3.
    Clark LC: Emulsions of perfluoronated solvents for intravenous gas transport. Fed Proc 34:1468–1477, 1981Google Scholar
  4. 4.
    Geyer RP: Perfluoronated blood replacement preparations. Excerpta Medica International Congress Series 486: 1978Google Scholar
  5. 5.
    Maugh TH: Blood substitute passes its first test. Science 206:205, 1981CrossRefGoogle Scholar
  6. 6.
    Gollan F, Clark LC: Organ perfusion with fluorocarbon fluid. Physiologist 9:191, 1966Google Scholar
  7. 7.
    Clark LC, Gollan F: Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science 152:1755–1757, 1966PubMedCrossRefGoogle Scholar
  8. 8.
    Lapin R, Freidman A, Levine E: The preoperative use of Fluosol-DA(20%) in major abdominal surgery. J Abd Surg 22:15, 1980Google Scholar
  9. 9.
    Geyer RP: Bloodless rats through the use of artificial blood substitutes. Fed Proc 34:1449–1505, 1975Google Scholar
  10. 10.
    Suyama T, Yokoyama K, Naito R: Development of a perfluorochemical whole blood substitute Fluosol-DA(20%): An overview of clinical studies with 185 patients. Prog Clin Biol Res 55:609–628, 1981PubMedGoogle Scholar
  11. 11.
    Sloviter HA, Petkovic M, OGoshi S, Yamada H: Dispersed fluorochemicals as substitutes for erythrocytes in intact animals. J Appl Physiol 2:666–668, 1969Google Scholar
  12. 12.
    Clark LC, Jr, Becanttini F, Kaplan S: The physiological effects of artificial blood made from inert organic oxygen solvents. Ala J Med Sci 9:16–29, 1972PubMedGoogle Scholar
  13. 13.
    Gould SA, Rosen AL, Sehgal LR, et al: How good are fluorocarbon emulsions as O2 carriers? Surg Forum 32:299–301, 1981Google Scholar
  14. 14.
    Geyer RP: Fluorocarbon-polyol artificial blood substitutes. N Engl J Med 289:1077–1082, 1973PubMedCrossRefGoogle Scholar
  15. 15.
    Glogar DH, Kloner RA, Muller J, et al: Fluorocarbons reduce myocardial ischemia damage after coronary occlusion. Science 211:1439–1441, 1981PubMedCrossRefGoogle Scholar
  16. 16.
    Peerless SJ, Ishikawa R, Hunter IG, Peerless MJ: Protective effect of Fluosol-DA in acute cerebral ischemia. Stroke 193:206–209, 1981Google Scholar
  17. 17.
    Oldham KT, Giuce KS, Gourley WK, Lobe TE: Treatments of intestinal ischemia with oxygenated intraluminal perfluorocarbons. Am J Surg 153:291–294, 1987PubMedCrossRefGoogle Scholar
  18. 18.
    Toyohira H, Taira A, Arikawa K, et al: Isolated heart perfusion with FC-43: An experimental study. Excerpta Medica International Congress Series 486: 1978Google Scholar
  19. 19.
    Mitsuno T, Ohyanagi H, Naito R: Clinical studies of a perfluorochemical whole blood substitute (Fluosol-DA): Summary of 186 cases. Ann Surg 195:60–69, 1982PubMedCrossRefGoogle Scholar
  20. 20.
    Tremper KK: The preoperative treatment of severely anemic patients with a perfluorochemical oxygen-transport fluid Fluosol-DA. N Engl J Med 307:277–283, 1982PubMedCrossRefGoogle Scholar
  21. 21.
    Atabek U, Spence RK, Pello M, et al: Pancreaticoduodenectomy without homologous blood transfusions in an anemic Jehovah’s Witness. Arch Surg 127:349–351, 1992PubMedGoogle Scholar
  22. 22.
    Draffehn J, Reichelt H: The toxicity of surface-active substances for emulsifying perfluorocarbon compounds as components of blood substitute preparations. Pharmazie 46:271–272, 1991PubMedGoogle Scholar
  23. 23.
    Lane TA, Lamkin GE: Increased infection mortality and decreased neutrophil migration due to a component of an artificial blood substitute. Blood 68:351–354, 1986PubMedGoogle Scholar
  24. 24.
    Kerins DM: Role of the perfluorocarbon Fluosol-DA in coronary angioplasty. Am J Med Sci 307:218–221, 1994PubMedCrossRefGoogle Scholar
  25. 25.
    Young LH, Jaffe CC, Revkin JH: Metabolic and functional effects of perfluorocarbon distal perfusion during coronary angioplasty. Am J Cardiol 15:986–990, 1990CrossRefGoogle Scholar
  26. 26.
    Goodin TH, Kaufman RJ, Richard TJ, Grossbard EB: The use of perfluorochemical oxygen carriers in surgical hemodilution. In pressGoogle Scholar
  27. 27.
    Cernaianu AC, Spence RK, Vassilidze TV, et al: A safety study of a perfluorochemical emulsion, oxygent™, in anesthetized surgical patients. Anesthesiology 81:A397, 1994CrossRefGoogle Scholar
  28. 28.
    Wahr JA, Trowborst A, Spence RK: A pilot study of the efficacy of an oxygen carrying emulsion, oxygent™, in patients undergoing surgical blood loss. Anesthesiology 81:A313, 1994CrossRefGoogle Scholar
  29. 29.
    Gronert G, Messick J, Cucciara R, et al: Paradoxical air embolism from a probe — patent foramen ovale. Anesthesiology 50:548–549, 1979PubMedCrossRefGoogle Scholar
  30. 30.
    Oka Y, Inoue T, Hong Y, et al: Retained intracardiac air. Transesophageal echocardiography for definition of incidence and monitoring removal by improved techniques. J Thorac Cardiovasc Surg 91:329–338, 1986PubMedGoogle Scholar
  31. 31.
    Butler B, Hills B: Transpulmonary passage of venous air emboli. J Appl Physiol 59:543–547, 1985PubMedGoogle Scholar
  32. 32.
    Justice C, Leach J, Edwards WS: The harmful effects in treatment of coronary air embolism during heart surgery. Ann Thorac Surg 14:45–53, 1972CrossRefGoogle Scholar
  33. 33.
    Perkins-Pearson N, Marshall W, Bedford R: Atrial pressures in the seated position. Anesthesiology 57:493–497, 1982PubMedCrossRefGoogle Scholar
  34. 34.
    Spiess BD, McCarthy R, Piotrowski D, Ivankovich AD: Protection from venous air embolism with fluorocarbon emulsion FC-43. J Surg Res 41:439–444, 1986PubMedCrossRefGoogle Scholar
  35. 35.
    Tuman KJ, Spiess BD, McCarthy RJ, et al: Cardiorespiratory effects of venous air embolism in dogs receiving a perfluorocarbon emulsion. J Neurosurg 65:238–244, 1986PubMedCrossRefGoogle Scholar
  36. 36.
    Spiess BD, Braverman B, Woronowicz AW, Ivankovich AD: Protection from cerebral air emboli with perfluorocarbons in rabbits. Stroke 17:1146–1149, 1986PubMedCrossRefGoogle Scholar
  37. 37.
    Menasch’e P, Pinard E, Desroches AM, et al: Fluorocarbons: A potential treatment of cerebral air emboli in open heart surgery. Ann Thorac Surg 40:494–497, 1985CrossRefGoogle Scholar
  38. 38.
    Spiess BD, McCarthy RJ, Tuman KJ, Ivankovich AD: Protection from coronary air embolism by a perfluorocarbon emulsion (FC-43). J Cardiothorac Anesth 1:210–215, 1987PubMedCrossRefGoogle Scholar
  39. 39.
    Cassuto Y, Nunnely SA, Fahri LE: Inert gas washout in rats: enhancement by fluorocarbon infusion. Aerosp Med 45:12–14, 1974PubMedGoogle Scholar
  40. 40.
    Spiess BD, McCarthy RJ, Tuman KJ: Treatment of decompression sickness with a perfluorocarbon emulsion (FC-43). Undersea Biomed Res 15:31–37, 1988PubMedGoogle Scholar
  41. 41.
    Novotny JA, Bridgewater BJ, Himm JF, Homer LD: Quantifying the effect of intravascular perfluorocarbon on xenon elimination from canine muscle. J Appl Physiol 74:1356–1360, 1993PubMedGoogle Scholar
  42. 42.
    Spiess BD, Cochran RP, Kunzelman K, et al: Cerebral protection from massive air embolism with a perfluorocarbon emulsion prime addition for cardiopulmonary bypass. Anesthesiology 81:A692, 1994CrossRefGoogle Scholar
  43. 43.
    Boernert P, Dreher W, Schneider W: 19F chemical shift imaging in perfluorocarbons. NMR Biomed 2:278–283, 1989CrossRefGoogle Scholar
  44. 44.
    Mason RP, Antich PP, Babcock EE, et al: Perfluorocarbon imaging in vivo. A 19F MRI study in tumor-bearing mice. Mag Res Imag 7:475–485, 1989CrossRefGoogle Scholar
  45. 45.
    Curtis SE, Fuhrman BP, Howland DF, et al: Cardiac output during liquid (perfluorocarbon) breathing in newborn piglets. Crit Care Med 19:225–230, 1991PubMedCrossRefGoogle Scholar
  46. 46.
    Leach CL, Fuhrman BP, Morin FC 3rd, Roth MG. Perfluorocarbon-associated gas exchange (partial liquid ventilation) in respiratory distress syndrome: A prospective, randomized, controlled study. Crit Care Med 21:1270–1278, 1993PubMedCrossRefGoogle Scholar
  47. 47.
    Coleman CN, Bump EA, Kramer RA. Chemical modifiers of cancer treatment. J Clin Oncol 6:709–733, 1988PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Bruce D. Spiess

There are no affiliations available

Personalised recommendations